Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/TUBB4B_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TUBB4B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TUBB4B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TUBB4B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TUBB4B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TUBB4B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/TUBB4B_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TUBB4B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TUBB4B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TUBB4B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TUBB4B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TUBB4B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00019067 | Cervix | CC | cell killing | 37/2311 | 188/18723 | 2.61e-03 | 1.80e-02 | 37 |
GO:0002443 | Cervix | CC | leukocyte mediated immunity | 73/2311 | 440/18723 | 5.01e-03 | 2.98e-02 | 73 |
GO:00024431 | Cervix | HSIL_HPV | leukocyte mediated immunity | 41/737 | 440/18723 | 3.14e-07 | 1.76e-05 | 41 |
GO:00024493 | Cervix | HSIL_HPV | lymphocyte mediated immunity | 35/737 | 350/18723 | 4.45e-07 | 2.36e-05 | 35 |
GO:000190611 | Cervix | HSIL_HPV | cell killing | 23/737 | 188/18723 | 1.45e-06 | 6.47e-05 | 23 |
GO:00019093 | Cervix | HSIL_HPV | leukocyte mediated cytotoxicity | 12/737 | 124/18723 | 3.60e-03 | 3.22e-02 | 12 |
GO:00024432 | Cervix | N_HPV | leukocyte mediated immunity | 39/534 | 440/18723 | 3.94e-10 | 2.24e-07 | 39 |
GO:000244911 | Cervix | N_HPV | lymphocyte mediated immunity | 32/534 | 350/18723 | 7.29e-09 | 1.58e-06 | 32 |
GO:000190621 | Cervix | N_HPV | cell killing | 22/534 | 188/18723 | 2.20e-08 | 3.03e-06 | 22 |
GO:000190911 | Cervix | N_HPV | leukocyte mediated cytotoxicity | 13/534 | 124/18723 | 5.46e-05 | 1.22e-03 | 13 |
GO:00019066 | Liver | Cyst | cell killing | 13/496 | 188/18723 | 1.55e-03 | 3.61e-02 | 13 |
GO:00019092 | Liver | Cyst | leukocyte mediated cytotoxicity | 10/496 | 124/18723 | 1.72e-03 | 3.84e-02 | 10 |
GO:00024433 | Oral cavity | EOLP | leukocyte mediated immunity | 73/2218 | 440/18723 | 1.78e-03 | 1.16e-02 | 73 |
GO:0001906 | Stomach | GC | cell killing | 22/1159 | 188/18723 | 3.03e-03 | 2.71e-02 | 22 |
GO:0002449 | Stomach | GC | lymphocyte mediated immunity | 34/1159 | 350/18723 | 6.25e-03 | 4.69e-02 | 34 |
GO:00019061 | Stomach | CAG with IM | cell killing | 21/1050 | 188/18723 | 2.04e-03 | 2.11e-02 | 21 |
GO:00024491 | Stomach | CAG with IM | lymphocyte mediated immunity | 33/1050 | 350/18723 | 2.50e-03 | 2.46e-02 | 33 |
GO:00019062 | Stomach | CSG | cell killing | 22/1034 | 188/18723 | 7.18e-04 | 1.00e-02 | 22 |
GO:00024492 | Stomach | CSG | lymphocyte mediated immunity | 33/1034 | 350/18723 | 1.96e-03 | 2.06e-02 | 33 |
GO:00019063 | Stomach | CAG | cell killing | 19/552 | 188/18723 | 3.13e-06 | 1.55e-04 | 19 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TUBB4B | SNV | Missense_Mutation | | c.1282N>A | p.Ala428Thr | p.A428T | P68371 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TUBB4B | SNV | Missense_Mutation | | c.1245G>A | p.Met415Ile | p.M415I | P68371 | protein_coding | tolerated_low_confidence(0.1) | benign(0.09) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
TUBB4B | SNV | Missense_Mutation | novel | c.795C>A | p.Phe265Leu | p.F265L | P68371 | protein_coding | deleterious_low_confidence(0.02) | benign(0.115) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
TUBB4B | SNV | Missense_Mutation | novel | c.1316N>G | p.Glu439Gly | p.E439G | P68371 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.932) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
TUBB4B | deletion | Frame_Shift_Del | novel | c.309delN | p.His105ThrfsTer16 | p.H105Tfs*16 | P68371 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TUBB4B | SNV | Missense_Mutation | | c.1075N>T | p.Arg359Trp | p.R359W | P68371 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.776) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TUBB4B | SNV | Missense_Mutation | | c.1234G>A | p.Glu412Lys | p.E412K | P68371 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.999) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
TUBB4B | SNV | Missense_Mutation | novel | c.282N>C | p.Gln94His | p.Q94H | P68371 | protein_coding | deleterious_low_confidence(0.03) | benign(0.013) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
TUBB4B | SNV | Missense_Mutation | novel | c.98C>T | p.Thr33Met | p.T33M | P68371 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.567) | TCGA-AA-3519-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
TUBB4B | SNV | Missense_Mutation | | c.371N>T | p.Ala124Val | p.A124V | P68371 | protein_coding | deleterious_low_confidence(0.04) | benign(0.019) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |